These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38767062)

  • 21. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
    Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
    Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cyclic guanosine monophosphate synthase-stimulator of interferon genes pathway as a potential target for tumor immunotherapy.
    Chen R; Liu M; Jiang Q; Meng X; Wei J
    Front Immunol; 2023; 14():1121603. PubMed ID: 37153627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2',3'-Cyclic GMP-AMP Dinucleotides for STING-Mediated Immune Modulation: Principles, Immunotherapeutic Potential, and Synthesis.
    Shang M; Lu K; Guan W; Cao S; Ren M; Zhou C
    ChemMedChem; 2022 Jan; 17(2):e202100671. PubMed ID: 34807508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of amidobenzimidazole STING receptor agonists with systemic activity.
    Ramanjulu JM; Pesiridis GS; Yang J; Concha N; Singhaus R; Zhang SY; Tran JL; Moore P; Lehmann S; Eberl HC; Muelbaier M; Schneck JL; Clemens J; Adam M; Mehlmann J; Romano J; Morales A; Kang J; Leister L; Graybill TL; Charnley AK; Ye G; Nevins N; Behnia K; Wolf AI; Kasparcova V; Nurse K; Wang L; Puhl AC; Li Y; Klein M; Hopson CB; Guss J; Bantscheff M; Bergamini G; Reilly MA; Lian Y; Duffy KJ; Adams J; Foley KP; Gough PJ; Marquis RW; Smothers J; Hoos A; Bertin J
    Nature; 2018 Dec; 564(7736):439-443. PubMed ID: 30405246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of STING agonist with anti-vascular RGD-(KLAKLAK)
    Czapla J; Drzyzga A; Ciepła J; Matuszczak S; Jarosz-Biej M; Pilny E; Cichoń T; Smolarczyk R
    Cancer Immunol Immunother; 2024 Jun; 73(8):148. PubMed ID: 38832958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.
    Da Y; Liu Y; Hu Y; Liu W; Ma J; Lu N; Zhang C; Zhang C
    Oncoimmunology; 2022; 11(1):2054105. PubMed ID: 35371622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delivery of STING agonists for cancer immunotherapy.
    Wang J; Meng F; Yeo Y
    Curr Opin Biotechnol; 2024 Jun; 87():103105. PubMed ID: 38461748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of Non-Nucleotide Small-Molecule STING Agonists
    Cherney EC; Zhang L; Lo J; Huynh T; Wei D; Ahuja V; Quesnelle C; Schieven GL; Futran A; Locke GA; Lin Z; Monereau L; Chaudhry C; Blum J; Li S; Fereshteh M; Li-Wang B; Gangwar S; Pan C; Chong C; Zhu X; Posy SL; Sack JS; Zhang P; Ruzanov M; Harner M; Akhtar F; Schroeder GM; Vite G; Fink B
    J Med Chem; 2022 Feb; 65(4):3518-3538. PubMed ID: 35108011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapy.
    Zhan M; Yu X; Zhao W; Peng Y; Peng S; Li J; Lu L
    J Nanobiotechnology; 2022 Jan; 20(1):23. PubMed ID: 34991618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
    Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
    Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.
    Motedayen Aval L; Pease JE; Sharma R; Pinato DJ
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LL-37 transports immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunity.
    Wei X; Zhang L; Yang Y; Hou Y; Xu Y; Wang Z; Su H; Han F; Han J; Liu P; Hu S; Koci MD; Sun X; Zhang C
    Cell Rep; 2022 May; 39(9):110880. PubMed ID: 35649354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
    Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A non-nucleotide agonist that binds covalently to cysteine residues of STING.
    Matsumoto K; Ni S; Arai H; Toyama T; Saito Y; Suzuki T; Dohmae N; Mukai K; Taguchi T
    Cell Struct Funct; 2023 Feb; 48(1):59-70. PubMed ID: 36575042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
    Hines JB; Kacew AJ; Sweis RF
    Curr Oncol Rep; 2023 Mar; 25(3):189-199. PubMed ID: 36705879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. cGAS-STING, an important pathway in cancer immunotherapy.
    Jiang M; Chen P; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; Ye L; He Y; Zhou C
    J Hematol Oncol; 2020 Jun; 13(1):81. PubMed ID: 32571374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour.
    Jeong SH; Yang MJ; Choi S; Kim J; Koh GY
    Nat Commun; 2021 Jul; 12(1):4405. PubMed ID: 34285232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel non-nucleotidic STING agonists for cancer immunotherapy.
    Berger G; Lawler SE
    Future Med Chem; 2018 Dec; 10(24):2767-2769. PubMed ID: 30526033
    [No Abstract]   [Full Text] [Related]  

  • 39. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis.
    Song C; Liu D; Liu S; Li D; Horecny I; Zhang X; Li P; Chen L; Miller M; Chowdhury R; Issa M; Shen R; Yan Y; Zhang F; Zhang L; Zhang L; Bai C; Feng J; Zhuang L; Zhang R; Li J; Wilkinson H; Liu J; Tao W
    Sci Rep; 2022 May; 12(1):8579. PubMed ID: 35595822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of STING by targeting a pocket in the transmembrane domain.
    Lu D; Shang G; Li J; Lu Y; Bai XC; Zhang X
    Nature; 2022 Apr; 604(7906):557-562. PubMed ID: 35388221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.